Investor Alert

Sept. 21, 2021, 6:42 a.m. EDT

Johnson & Johnson says Phase 3 trial data confirms 'strong and long-lasting' protection from COVID-19 vaccine

Johnson & Johnson (NYS:JNJ) said Tuesday data from a Phase 3 trial and real-world evidence confirm that its single-shot COVID-19 vaccine offers strong and long-lasting protection against hospitalization and death. The company said further data shows that a booster shot offers increased protection. Data shows 94% protection in the U.S. with a booster given at two months, a four-fold increase in antibodies when given at two months and a 12-fold increase when given at six months. "The safety profile of the vaccine remained consistent and was generally well-tolerated when administered as a booster," the company said in a statement. The company has submitted data from the trial to the U.S. Food and Drug Administration and other regulators, the World Health Organization and National Immunization Technical Advisory Groups (NITAGs) worldwide. The Phase 3 trial included 390,000 people who got the J&J one-shot vaccine versus about 1.52 million unvaccinated people matched on age, sex, time, three-digit zip code and comorbidities and predictors for COVID-19 infection severity. The trial was conducted from March to late July 2021. Shares rose 1.1% premarket and have gained 4% in the year through Monday's close, while the Dow Jones Industrial Average (DOW:DJIA) has gained 11% and the S&P 500 (S&P:SPX) has gained 16%.

Link to MarketWatch's Slice.